Pharma-Bio Serv, Inc. (PBSV) intrinsic value & 10-year financials
Pharma-Bio Serv, Inc. (PBSV) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 8.2% a year to $9.0M, with an average return on invested capital of 0.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.40
- Market cap
- $9.2M
- Revenue (FY2025)
- $9.0M
- Revenue growth (10-yr CAGR)
- -8.2%
- ROIC (10-yr avg)
- 0.7%
- Free cash flow (FY2025)
- -$221.5K
PBSV 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $9.0M | -$100.5K | -$0.00 | -$221.5K | -7.1% | -8.2% |
| FY2024 | $9.5M | -$777.6K | -$0.03 | -$726.4K | -13.5% | -20.0% |
| FY2023 | $17.0M | $1.3M | $0.06 | $1.9M | 6.6% | 20.9% |
| FY2022 | $19.4M | $1.0M | — | $573.2K | 6.1% | 45.5% |
| FY2021 | $20.1M | -$2.1M | — | $794.0K | -19.2% | -94.0% |
| FY2020 | $21.6M | $2.1M | — | $1.5M | 10.3% | 34.8% |
| FY2019 | $19.5M | $2.1M | — | -$2.3M | 10.7% | 37.8% |
| FY2018 | $17.8M | $1.3M | — | $3.6M | -7.1% | -3.1% |
| FY2017 | $13.3M | -$1.4M | -$0.06 | -$2.0M | -10.7% | -6.7% |
| FY2016 | $19.5M | -$256.6K | -$0.01 | -$1.1M | -0.5% | -0.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Pharma-Bio Serv, Inc. is facing top-line stagnation, with revenue contracting over the decade.
Pharma-Bio Serv, Inc. has historically struggled to out-earn its cost of capital, averaging just 0.7% ROIC.
Pharma-Bio Serv, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Pharma-Bio Serv, Inc. is modeled at -8.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.39 per share.